The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Placebo‐controlled trial of mianserin and maprotiline in primary depressive illness: a preliminary report.
Open accessAbstract
1 Preliminary results of a double‐blind placebo‐controlled trial of mianserin and maprotiline carried out in 58 outpatients with primary depressive illness are reported. 2 Patients received six weeks' treatment with 30 to 90 mg mianserin, 75 to 225 mg maprotiline or one to three capsules of placebo, all medication being taken at night. 3 There were statistically significant improvements in each treatment group and a better response to mianserin than to placebo or maprotiline on the Hamilton Rating Scale for Depression, after one week's treatment. 4 Neither mianserin nor maprotiline was superior to placebo after two or four weeks' treatment and relatively few patients completed six weeks' treatment because of a generally unsatisfactory response. 5 Unwanted effects were not particularly troublesome, though mianserin and maprotiline caused more drowsiness and blurred vision than did placebo, while maptrotiline produced more constipation than either of the other two treatments. 6 The importance of placebo‐ controlled trials of antidepressants is emphasized and the precautions that should be taken when they are carried out in outpatients are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In depressed outpatients, mianserin 30-90mg was significantly better than placebo at reducing early insomnia on day 14 (p<0.05), with no other significant between-group differences on HAMDS.
“MIA sig better than PLC at reducing early insomnia day 14 (p<0.05), no other sig between-group differences HAMDS”
From Antidepressants and their effect on sleep (2005) · cites this paper as Edwards, 1983
The Patients and Treatment sections identify depressed outpatients receiving 30–90 mg of mianserin. The Hamilton Rating Scale results (Dosage section; page unavailable) say the significant advantage over placebo in total scores occurred at day 7 and could not be demonstrated at day 14. Our copy does not report a significant day-14 difference for early insomnia (p<0.05), so that specific finding is unsupported. (LLM, conf=0.78)
Experimental — accuracy not yet measuredIn depressed outpatients, there were no significant between-group differences on LSEQ, but all groups significantly reduced throughout (including placebo).
“no sig between-group differences LSEQ, but all sig reduced throughout (including PLC)”
From Antidepressants and their effect on sleep (2005) · cites this paper as Edwards, 1983
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exemplification of a Method for Scaling Life Events: The PERI Life Events Scale
Dohrenwend, B. S., Askenasy, A. R., Krasnoff, L., & Dohrenwend, B. P. (1978) · Journal of Health and Social Behavior · doi:10.2307/2136536 · Cited by 1,211
Flagged first, then by citations
Research works printed but not linked: 22
- 10.1016/S0140-6736(82)92349-2 · DOI
- 10.1001/jama.1955.02960340022006 · DOI
- 10.1192/bjp.111.477.659 · DOI
- CLAGHORN J.L., 1977, A double‐blind study of maprotiline (Ludiomil) and imipramine in depressed outpatients., Curr. Therapeut. Res., 22, 446
- 10.1192/bjp.137.6.522 · DOI
- EDWARDS J.G., 1982, Mianserin, maprotiline and intracardiac conduction., Br. J. clin. Pharmac., 15, 249S, 10.1111/j.1365-2125.1983.tb05872.x · DOI
- 10.1185/03007997409114763 · DOI
- EYSENCK H.J., 1975, The Manual of the Eysenck Personality Questionnaire.
- 10.1001/archpsyc.1972.01750190059011 · DOI
- 10.1136/jnnp.23.1.56 · DOI · Paper page
- JUKES A.M., 1975, A comparison of maprotiline (Ludiomil) and placebo in the treatment of depression., J. Int. Med. Res., 3, 84
- KENDALL R.E., 1968, The Classification of Depressive Illness.
- 10.5694/j.1326-5377.1975.tb105901.x · DOI
- 10.1136/bmj.1.5439.881 · DOI
- MURPHY J.E., 1976, Mianserin in the treatment of depression in general practice., Practitioner, 217, 135
- PERRY G.F., 1978, Clinical study of mianserin, imipramine and placebo in depression: blood level and MHPG correlation., Pharmac., 5, 35
- SEDGWICK E.M., 1982, Mianserin, maprotiline and the electroencephalogram., Br. J. clin. Pharmac., 15, 255S, 10.1111/j.1365-2125.1983.tb05873.x · DOI
- SMITH A.H.W., 1978, Placebocontrolled double‐blind trial of mianserin hydrochloride., Br. J. clin. Pharm., 5, 67
- 10.1192/bjp.128.2.156 · DOI
- STEWART J.W., 1982, Efficacy of mianserin in mildly depressed patients, Psychopharmacol. Bull., 18, 68
- 10.1016/0165-0327(80)90001-4 · DOI
- VELDE C.D., 1981, A comparison of maprotiline and imipramine in neurotic depression., J. clin. Psychiat., 42, 138
Cited by
Sorted by citations
Antidepressants and their effect on sleep
Mayers, A. G., & Baldwin, D. S. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.726 · Cited by 323
Metadata
- Authors
- Edwards, J., & Goldie, A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1983-04
- Volume
- 15
- Issue
- S2
- Pages
- 239S-248S
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC1427875
- OpenAlex
- W2024629050
- Cited by
- 15
- References
- 1
- Citations by year
- 2024: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- mianserin, maprotiline, depression, antidepressants, outpatients, adverse effects, sleepiness, constipation, blurred vision, treatment response
- MeSH terms
- Adolescent, Adult, Aged, Anthracenes, Clinical Trials as Topic, Depressive Disorder, Dibenzazepines, Double-Blind Method, Female, Humans, Male, Maprotiline, Mianserin, Middle Aged, Placebos, Psychiatric Status Rating Scales, Sex Factors, Sleep
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
